| 王 珊,吴黎黎,章宝芝,邵璇璇,鲍颍松,汪青松.血清PRDX1、FGF4、Hepc25水平与急性缺血性脑卒中患者病情及预后的关系研究[J].,2021,(19):3733-3737 |
| 血清PRDX1、FGF4、Hepc25水平与急性缺血性脑卒中患者病情及预后的关系研究 |
| Study on the Relationship between Serum PRDX1, FGF4, Hepc25 Levels and the Condition and Prognosis of Patients with Acute Ischemic Stroke |
| 投稿时间：2021-03-28 修订日期：2021-04-22 |
| DOI：10.13241/j.cnki.pmb.2021.19.027 |
| 中文关键词: 过氧化还原蛋白1 病情 成纤维细胞生长因子4 铁调素25 急性缺血性脑卒中 预后 |
| 英文关键词: Peroxiredoxin 1 State of an illness Fibroblast growth factor 4 Hepcidin25 Acute ischemic stroke Prognosis |
| 基金项目:安徽省自然科学基金项目（1708085QH204） |
|
| 摘要点击次数: 491 |
| 全文下载次数: 296 |
| 中文摘要: |
| 摘要 目的：探讨血清过氧化还原蛋白1（PRDX1）、成纤维细胞生长因子4（FGF4）、铁调素25（Hepc25）与急性缺血性脑卒中（AIS）患者病情严重程度和预后的关系。方法：选择2018年1月到2020年1月我院收治的73例AIS患者（AIS组）和同期于我院进行体检的56例健康者（对照组），根据入院当日美国国立卫生研究院卒中量表（NIHSS）评分将AIS组进一步分为轻症组（NIHSS评分＜6分，21例）、中症组（6分≤NIHSS评分＜13分，38例）、重症组（NIHSS评分≥13分，14例）。根据患者出院后改良Rankin量表(mRS)评分将其分为预后不良组（≥3分，18例）和预后良好组（0～2分，55例）。检测所有受试者血清PRDX1、FGF4、Hepc25水平，分析PRDX1、FGF4、Hepc25与NIHSS、mRS评分相关性，分析AIS患者预后的影响因素。结果：AIS组血清PRDX1、FGF4、Hepc25水平均高于对照组（P＜0.05），重症组血清PRDX1、FGF4、Hepc25水平高于中症组和轻度症组（P＜0.05），且中症组血清PRDX1、FGF4、Hepc25水平高于轻症组（P＜0.05），预后不良组血清PRDX1、FGF4、Hepc25水平高于预后良好组（P＜0.05）。AIS患者血清PRDX1、FGF4、Hepc25水平均与NHISS评分、mRS评分呈正相关（r=0.636、0.794、0.682；0.619、0.705、0.713，P＜0.05）。单因素分析结果显示年龄、高血压、糖尿病、入院时NIHSS评分与AIS患者预后有关（P＜0.05），多因素Logistic回归分析结果显示入院时高NIHSS评分，高血清PRDX1、FGF4、Hepc25水平是AIS患者预后不良的危险因素（P＜0.05）。结论：AIS患者血清RDX1、FGF4、Hepc25水平明显升高，高水平RDX1、FGF4、Hepc25与AIS患者严重神经缺损和预后不良密切相关，可以作为AIS预后评估的辅助生物学指标。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum peroxiredoxin 1 (PRDX1), fibroblast growth factor 4 (FGF4), and hepcidin25 (Hepc25) and the severity of illness and prognosis of patients with acute ischemic stroke (AIS). Methods: 73 patients with AIS (AIS group) who were admitted to our hospital from January 2018 to January 2020 and 56 healthy patients (control group) who underwent physical examination in our hospital during the same period were selected. According to the national institutes of health stroke scale (NIHSS) scores , AIS group were divided into mild group (NIHSS score < 6 scores, 21 cases), moderate group (6 scores ≤NIHSS score＜13 scores, 38 cases) and severe group (NIHSS score ≥13 scores, 14 cases). According to the modified Rankin scale (mRS), the patients was divided into good prognosis group (0 ~ 2 scores, 55 cases) and poor prognosis group (≥3 scores , 18 cases). Serum PRDX1, FGF4 and Hepc25 levels in all subjects were detected, the correlation between PRDX1, FGF4, Hepc25 and NIHSS and mRS scores were analyzed, the clinical data of patients with different prognosis were compared, the prognostic factors of AIS patients were analyzed. Results: The serum PRDX1, FGF4, Hepc25 levels in AIS group were higher than those in control group (P<0.05), serum PRDX1, FGF4, Hepc25 levels in severe group were higher than those in moderate group and mild group (P<0.05), the serum PRDX1, FGF4, Hepc25 levels in moderate group were higher than those in the mild group (P<0.05), and serum PRDX1, FGF4, Hepc25 levels in poor prognosis group were higher than those in good prognosis group (P<0.05). Serum PRDX1, FGF4 and Hepc25 levels of patients with AIS were positively correlated with NHISS score and mRS score (r=0.636, 0.794, 0.682; 0.619, 0.705, 0.713, P<0.05). Univariate analysis showed that age, hypertension, diabetes, NIHSS score on admission were related to prognosis (P<0.05). Regression analysis showed that high NIHSS score at admission, high serum PRDX1, FGF4 and Hepc25 levels were risk factors for poor prognosis of patients with AIS (P<0.05). Conclusion: The serum RDX1, FGF4 and Hepc25 levels in patients with AIS are significantly increased. High level of RDX1, FGF4 and Hepc25 are closely related to severe nerve defects and poor prognosis in patients with AIS, and which can be used as biological indicators for the prognosis assessment of AIS. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
